News
Apollo TMS Therapy delivers targeted stimulation to specific brain regions responsible for mood and emotional regulation.The ...
Please provide your email address to receive an email when new articles are posted on . Transcranial magnetic stimulation targets the central executive network. 80% of patients responded by 20 ...
Zacks Investment Research on MSN
BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care
BrainsWay Ltd. BWAY recently secured FDA clearance for an accelerated treatment protocol using its Deep Transcranial Magnetic ...
NEW YORK ― Transcranial magnetic stimulation (TMS) is a cost-effective treatment option for patients with resistant major depressive disorder (MDD), according to a new economic analysis. "It's mainly ...
Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression ...
Advancing Mental Health Care for Adolescents A young man receiving Apollo TMS Therapy by neurocare — a non-invasive, ...
Brainsway ( ($BWAY) ) has issued an update. On September 16, 2025, BrainsWay Ltd. announced that it received FDA clearance for an accelerated Deep ...
Apollo transcranial magnetic stimulation (TMS) therapy devices by neurocare group have received FDA clearance for treating ...
SaveHealth reports on depression medications, emphasizing individual responses to treatments and the importance of combining ...
LOS ANGELES, Nov. 28, 2017 (GLOBE NEWSWIRE) -- TMS Neuro Institute, led under the direction of Dr. Gennady Musher, MD, Phd, and Faculty Member at UCLA, has officially opened its doors in Los Angeles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback